Cingulate

Update in progress

CING (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cingulate Inc. is a biopharmaceutical company using its drug-delivery platform to develop treatments for ADHD and anxiety in the United States. Its lead candidate, CTx-1301 (dexmethylphenidate), is in Phase 3 for ADHD in children, adolescents, and adults. CTx-2103 (buspirone) is in formulation development for anxiety. The company plans to begin a clinical program for CTx-1302 (dextroamphetamine) for ADHD. Founded 2012, based in Kansas City, Kansas.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.17; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive